Background: Influenza is a respiratory infection caused primarily by influenza A and B viruses. Vaccination is the most effective way to prevent influenza and its complications. The National Advisory Committee on Immunization (NACI) provides recommendations regarding seasonal influenza vaccines annually to the Public Health Agency of Canada (PHAC).
Introduction
Influenza and pneumonia is ranked among the top 10 leading causes of death in Canada (1) . Although the burden of influenza can vary from year to year, it is estimated that in a given year, there are an average of 12,200 hospitalizations related to influenza (2) and approximately 3,500 deaths attributable to influenza (3) . The National Advisory Committee on Immunization (NACI) provides recommendations regarding seasonal influenza vaccines annually to the Public Health Agency of Canada (PHAC). The objective of this article is to summarize the NACI recommendations for the use of seasonal influenza vaccine for the 2017-2018 influenza season. Complete details can be found in the Statement on Seasonal Influenza Vaccine for 2017-2018 (4) .
Methods
In the preparation of the 2017-2018 seasonal influenza vaccine recommendations, NACI's Influenza Working Group (IWG) identified and reviewed evidence regarding the administration of live attenuated influenza vaccine (LAIV) in egg-allergic individuals and vaccine effectiveness of LAIV and inactivated influenza vaccine (IIV) in children and adolescents 2-17 years of age. Following the review and analysis of this information, the IWG proposed updated recommendations for vaccine use to NACI, based on NACI's evidence-based process for developing recommendations (5) . NACI critically appraised the available evidence and approved the specific recommendations brought forward. Complete details of the literature review, rationale and relevant considerations for the updated recommendations can be found in the Addendum -LAIV Use in Egg Allergic Individuals (6), the Addendum -LAIV Use in Children and Adolescents (7) ,
and the Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2017-2018 (4).
For the review of LAIV use in egg-allergic individuals, data were obtained from three prospective cohort studies in the United Kingdom (UK) and Canada (8) (9) (10) . Post-licensure safety data from the Canadian Adverse Events Following Immunization Surveillance System (CAEFISS) was analyzed to seek reports of adverse events in influenza vaccine recipients who describe a history of allergy to eggs.
Data on LAIV vaccine effectiveness in children and adolescents were obtained primarily from American studies using the test-negative design: the United States Influenza Vaccine Effectiveness Network (US Flu VE Network) (2010-2016) (11) (12) (13) (14) , the Influenza Clinical Investigation for Children (ICICLE) study (27) . These studies used the test-negative design (21) (22) (23) (24) (25) (26) , with one prospective cohort study (27) and two cluster randomized trials (28, 29) .
This article also presents information not provided in the published addenda or statement: figures summarizing the LAIV vaccine effectiveness data from the cited studies, by influenza season and influenza strain, as well as LAIV vaccine effectiveness data used to inform NACI's decision that were not publicly available when the Addendum was finalized, but have subsequently been published (30, 31) .
Results

New for the 2017-2018 influenza season
There were two changes in NACI recommendations for the use of seasonal influenza vaccine for the 2017-2018 influenza season. Both changes related to updated recommendations on the use of LAIV.
LAIV is safe for egg-allergic individuals
All influenza vaccine products authorized for use in Canada are manufactured from influenza virus grown in chicken eggs, which may result in the vaccines containing trace amounts of residual egg protein. However, the safety of LAIV in egg-allergic individuals has now been studied in more than 1,100 children and adolescents (2-18 years of age) in the UK and Canada (8) (9) (10) . After careful review of recently published studies, NACI concludes that egg-allergic individuals may be vaccinated against influenza using the low ovalbumin-containing LAIV licensed for use in Canada. The full dose of LAIV may be used without prior vaccine skin test and in any settings where vaccines are routinely administered. LAIV also appears to be well tolerated in individuals with a history of stable asthma or recurrent wheeze; however, it remains contraindicated for individuals with severe asthma (defined as currently on oral or high-dose inhaled glucocorticosteroids or active wheezing) or for those with medically attended wheezing in the seven days prior to immunization. The use of LAIV in egg-allergic individuals is a change from previous NACI statements. 2016-2017 (32) , NACI recommended the preferential use of LAIV in children and adolescents 2-17 years of age who did not have contraindications to the vaccine. This recommendation was based upon randomized placebo controlled studies and post-marketing safety data that showed LAIV to be safe, efficacious and immunogenic in children and to provide better protection against influenza than trivalent IIV, especially in young children (less than six years of age), with weaker evidence of superior efficacy in older children (33) . (34) . LAIV continued to be recommended for use in children in the UK and Finland for the 2016-2017 season (35) . Studies conducted in both of these countries and in Canada found a statistically significant overall protective effect of LAIV in children for 2015-2016, although sample sizes limited the precision of those estimates (22, 24, 27) . The United States Food and Drug Administration (US FDA) has also determined that specific regulatory action for LAIV was not necessary at the time, following a review of manufacturing and clinical data supporting licensure and the totality of evidence presented at the June ADVISORY COMMITTEE STATEMENT 2016 ACIP meeting, and continues to find that the benefits of quadrivalent LAIV outweigh any potential risks (36) . Quadrivalent LAIV remains licensed for use in the US. The FDA's determination was made taking into account the limitations of observational studies in estimating vaccine effectiveness and the seasonal variability of influenza vaccine effectiveness.
After careful review of available studies from the last several influenza seasons, NACI concludes that the current evidence is consistent with LAIVs providing comparable protection against influenza to that afforded by IIV in various jurisdictions and has revised its recommendations on the use of influenza vaccine in children and adolescents 2-17 years of age:
1. In children and adolescents without contraindications to the vaccine, any of the following vaccines can be used: quadrivalent LAIV, quadrivalent inactivated influenza vaccine (QIV) or trivalent inactivated influenza vaccine (TIV). 2. The current evidence does not support a recommendation for the preferential use of LAIV in children and adolescents 2-17 years of age.
Given the burden of influenza B disease in children and the potential for lineage mismatch between the predominant circulating strain of influenza B and the strain in a trivalent vaccine, NACI continues to recommend that a quadrivalent formulation of influenza vaccine be used in children and adolescents 2-17 years of age. If a quadrivalent vaccine is not available, TIV should be used.
The observational study data reviewed highlight the challenge in interpreting the vaccine effectiveness of LAIV and IIV when point estimates by influenza subtype are derived based on small sample sizes associated with wide confidence intervals. Therefore, in making its recommendations, NACI recognizes the need to continue to closely monitor the data on the vaccine effectiveness of LAIV by influenza subtype and the relative effectiveness of LAIV compared to IIV. NACI has also identified the need for further research to address current knowledge gaps:
3. NACI strongly encourages further multidisciplinary (e.g. epidemiology, immunology, virology) research to investigate the reasons for the discordant 2015-2016 vaccine effectiveness estimates between studies and explanations for poor LAIV effectiveness against A(H1N1)pdm09 reported in some studies. 4. NACI strongly recommends that sufficient resources be provided to enhance influenza-related research and sentinel surveillance systems in Canada to improve the evaluation of influenza vaccine efficacy and effectiveness to provide the best possible evidence for Canadian influenza vaccination programs and recommendations. Recommended influenza vaccine options by specific age and risk groups and by dosage and route of administration by age are summarized in Table 2 and Table 3 , respectively.
Conclusion
NACI continues to recommend annual influenza vaccination for all individuals aged six months and older (noting product-specific age indications and contraindications), with particular focus on people at high risk of influenza-related complications or hospitalization, including all pregnant women; people capable of transmitting influenza to those at high risk; and others as indicated. For the 2017-2018 influenza season, NACI has also updated LAIV use recommendations: 1) egg-allergic individuals may be vaccinated against influenza using the low ovalbumin-containing LAIV licensed for use in Canada, and 2) LAIV continues to be recommended for use in children and adolescents 2-17 years of age, but is no longer recommended preferentially. 1 For each study in the forest plot, the black circle represents the vaccine effectiveness point estimate and the vertical bar represents the corresponding 95% confidence interval. The 95% confidence interval lower limits are truncated at -40% 2 The Canadian SPSN reported unadjusted vaccine effectiveness estimates 3 The Finland national cohort study reported vaccine effectiveness against influenza A in children two years of age 1 For each study in the forest plot, the black circle represents the vaccine effectiveness point estimate and the vertical bar represents the corresponding 95% confidence interval. The 95% confidence interval lower limits are truncated at -40% 2 The ICICLE study reported vaccine effectiveness against influenza B/Yamagata for the 2013-2014 influenza season 3 The Finland national cohort study reported vaccine effectiveness in children two years of age
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